Division of Nephrology, Tufts Medical Center, Boston, Massachusetts.
JAMA. 2015 Feb 24;313(8):837-46. doi: 10.1001/jama.2015.0602.
Because early-stage kidney disease is asymptomatic and is associated with both morbidity and mortality, laboratory measurements are required for its detection.
To summarize evidence supporting the use of laboratory tests for glomerular filtration rate (GFR) and albuminuria to detect and stage acute kidney injury, acute kidney diseases and disorders, and chronic kidney disease in adults.
We reviewed recent guidelines from various professional groups identified via the National Guideline Clearing House and author knowledge, and systematically searched MEDLINE for other sources of evidence for selected topics.
The KDIGO (Kidney Disease Improving Global Outcomes) guidelines define and stage acute and chronic kidney diseases by GFR and albuminuria. For initial assessment of GFR, measuring serum creatinine and reporting estimated GFR based on serum creatinine (eGFRcr) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation is recommended. If confirmation of GFR is required because of conditions that affect serum creatinine independent of GFR (eg, extremes of muscle mass or diet), or interference with the assay, cystatin C should be measured and estimated GFR should be calculated and reported using cystatin C (eGFRcys) and serum creatinine (eGFRcr-cys) or GFR should be measured directly using a clearance procedure. Initial assessment of albuminuria includes measuring urine albumin and creatinine in an untimed spot urine collection and reporting albumin-to-creatinine ratio. If confirmation of albuminuria is required because of diurnal variation or conditions affecting creatinine excretion, such as extremes of muscle mass or diet, the albumin excretion rate should be measured from a timed urine collection.
Detection and staging of acute and chronic kidney diseases can be relatively simple. Because of the morbidity and mortality associated with kidney disease, early diagnosis is important and should be pursued in at-risk populations.
由于早期肾脏疾病无症状,且与发病率和死亡率相关,因此需要进行实验室检测以发现肾脏疾病。
总结支持使用实验室检测肾小球滤过率(GFR)和白蛋白尿来检测和分期急性肾损伤、急性肾疾病和障碍以及成人慢性肾脏病的证据。
我们通过国家指南清理中心和作者知识,对最近来自不同专业团体的指南进行了综述,并系统地在 MEDLINE 上搜索了其他选定主题的证据来源。
KDIGO(肾脏疾病:改善全球预后)指南通过 GFR 和白蛋白尿来定义和分期急性和慢性肾脏病。对于 GFR 的初始评估,建议测量血清肌酐并使用基于血清肌酐的慢性肾脏病流行病学合作组(CKD-EPI)2009 方程报告估算肾小球滤过率(eGFRcr)。如果由于独立于 GFR 影响血清肌酐的条件(例如肌肉量或饮食的极端情况)或干扰检测而需要确认 GFR,则应测量胱抑素 C,并使用胱抑素 C(eGFRcys)和血清肌酐(eGFRcr-cys)计算和报告估算肾小球滤过率,或直接使用清除程序测量 GFR。白蛋白尿的初始评估包括测量非定时随机尿样中的尿白蛋白和肌酐,并报告白蛋白与肌酐的比值。如果由于昼夜变化或影响肌酐排泄的条件(例如肌肉量或饮食的极端情况)需要确认白蛋白尿,则应从定时尿样中测量白蛋白排泄率。
急性和慢性肾脏病的检测和分期可以相对简单。由于肾脏疾病与发病率和死亡率相关,因此早期诊断很重要,应在高危人群中进行。